Tirzepatide/Bimagrumab

替尔泊肽/比玛卢单抗

Report date: 2025/06/04 16:49:34

Base Information

Drug NameTirzepatide/Bimagrumab

Drug Alias NameLY-900042

ClassificationOther

Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsActivin receptor type-2B inhibitors

TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorActivin receptor type-2B

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes Tirzepatide Bimagrumab

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A